OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
VYGR
Voyager Therapeutics, Inc.
There isn't enough reported data to score VYGR yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
VYGR Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Strong |
VYGR's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
VYGR PE Valuation
VYGR has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
VYGR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect VYGR's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over VYGR on earnings quality, reporting a profit while its opponent remains loss making.
VYGR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.74 | +$0.42 |
| Q2 2026 | -$1.81 | +$0.04 |
| Q1 2026 | -$1.98 | -$0.52 |
| Q4 2025 | -$2.04 | -$0.91 |
| Q3 2025 | -$2.16 | -466% |
| Q2 2025 | -$1.85 | -1256% |
| Q1 2025 | -$1.46 | -$1.29 |
| Q4 2024 | -$1.13 | -138% |
VYGR is still losing money, but less than at its worst: $1.74 per share over the past year, against $2.45 at its worst in late 2021.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over VYGR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over VYGR on profitability, with a higher operating margin.
VYGR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4M | -70% |
| Q2 2026 | $3.2M | -39% |
| Q1 2026 | $2.6M | -60% |
| Q4 2025 | $15.3M | +144% |
| Q3 2025 | $13.4M | -46% |
| Q2 2025 | $5.2M | -82% |
| Q1 2025 | $6.5M | -67% |
| Q4 2024 | $6.3M | -93% |
VYGR's revenue has slid since its 2023 peak: $4M last quarter, down 70% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -658% | -429 points |
| Q2 2026 | -834% | -130 points |
| Q1 2026 | -1167% | -631 points |
| Q4 2025 | -195% | +415 points |
| Q3 2025 | -229% | -173 points |
| Q2 2025 | -704% | -654 points |
| Q1 2025 | -536% | -453 points |
| Q4 2024 | -610% | -670 points |
VYGR's operating margin was −658% last quarter, down 429 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over VYGR on cash generation, producing positive trailing cash flow while its opponent burns cash.
VYGR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$19.7M | +$11.6M |
| Q2 2026 | -$25.8M | +$8.5M |
| Q1 2026 | -$33.4M | +$5.1M |
| Q4 2025 | -$30.9M | -$16.2M |
| Q3 2025 | -$31.3M | -$3M |
| Q2 2025 | -$34.4M | -$1.8M |
| Q1 2025 | -$38.6M | -168% |
| Q4 2024 | -$14.7M | +$9.8M |
VYGR has burned cash in almost every quarter: −$110M over the past year, against −$119M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
VYGR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.1% | +1.3M shares |
| 1 year | +5.1% | +3M shares |
| 3 years | +41% | +18M shares |
| 5 years | +64% | +24M shares |
| Available history | +72% | +25.9M shares |
VYGR has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
VYGR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | -8.0x | Net Cash |
| Q4 2023 | -0.5x | Net Cash |
| Q3 2023 | -1.4x | Net Cash |
| Q2 2023 | -2.6x | Net Cash |
| Q1 2023 | -2.7x | Net Cash |
| Q2 2021 | -10.6x | Net Cash |
| Q1 2021 | -3.9x | Net Cash |
| Q4 2020 | -3.4x | Net Cash |
VYGR has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
VYGR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.9 | Oversold |
| Stochastic | 4.6 | Oversold |
VYGR's weekly RSI is 27 (oversold) and its Stochastic is 5 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
VYGR PE vs Healthcare Sector
| Metric | VYGR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
VYGR has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over VYGR on trend strength, trading above more of its moving averages.
VYGR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.06 | 17% below |
| 20 week MA | $2.81 | 40% below |
| 50 week MA | $3.45 | 51% below |
| 100 week MA | $3.74 | 55% below |
| 200 week MA | $5.97 | 72% below |
VYGR is in a downtrend: it's below all five of its weekly moving averages, and 72% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over VYGR on returns for 2026, with the stronger performance.
VYGR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.9 | $7.98 | -43% |
| 2021 | $7.98 | $2.93 | -63% |
| 2022 | $2.93 | $5.56 | +90% |
| 2023 | $5.56 | $8.44 | +52% |
| 2024 | $8.44 | $5.74 | -32% |
| 2025 | $5.74 | $4.08 | -29% |
| 2026 YTD | $4.08 | $1.70 | -58% |
VYGR has finished lower in four of the last six years. It's down 58% so far in 2026.